| Ytd | -39.89% | |
| 1y | -67.70% |
| Open | 0.40 | Prev Close | 0.38 | Low | 0.37 | High | 0.40 | Mkt Cap | 18.52M |
| Vol | 136.03K | Avg Vol | 756.20K | EPS | -1.24 | P/E | -0.31 | Forward P/E | -0.86 |
| Beta | 0.29 | Short Ratio | 2.09 | Inst. Own | 72.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 0.38 | 200-d Avg | 0.71 | 1yr Est | 12.00 |
HOWL News
Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's af
WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “W
Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular
Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expect
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “We
Company continues to evaluate strategic options to maximize shareholder value Company continues to e
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the
Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have earned a consensus recom
Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 24,678 shares
Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 24,962 shares
Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a d
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S.
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, whi
Fast Track Designation underscores the promise of Werewolf's INDUKINE™ platform WATERTOWN, Mass., Oc
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “W
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025,
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “W
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “W
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that i
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after
The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their co
OnThursday, 137 stocks made new 52-week lows.
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The compan
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday.
On Thursday, 112 stocks made new 52-week lows.
Tuesday's session saw 52 companies set new 52-week lows.
On Monday, 524 stocks hit new 52-week lows.
Wednesday's session saw 107 companies set new 52-week lows.
Gainers
During Tuesday's morning trading, 87 companies set new 52-week lows.